Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.67 |
| ▸ | NAAA | Q02083 | 1/20 | 0.62 |
| ▸ | EPHX1 | P07099 | 8/20 | 0.61 |
| ▸ | FAAH | O00519 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.52 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16582460 | 1.00 | CASP2 (0.67) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL14621023 | 1.00 | CASP2 (0.67) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL6281759 | 1.00 | CASP2 (0.67) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL23567378 | 1.00 | CASP2 (0.67) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL6120008 | 1.00 | CASP2 (0.67) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL23567381 | 1.00 | CASP2 (0.67) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL5327335 | 1.00 | CASP2 (0.67) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL5331194 | 1.00 | CASP2 (0.67) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL462832 | 0.98 | CASP2 (0.63) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL3310816 | 0.91 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021126990-A1 | OXYTOCIN DERIVATIVES WITH IMPROVED PROPERTIES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-06-24 | — | — | WO | disclosed |
| US-7994152-B2 | Method of treating a cancer by administering A 2′,5′-oligoadenylate analog | SANKYO COMPANY, LIMITED (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7994152-B2 | Method of treating a cancer by administering A 2′,5′-oligoadenylate analog | SANKYO COMPANY, LIMITED (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20100035976-A1 | Method of treating a tumor or a viral disease by administering a 2' , 5' -oligoadenylate analog | SANKYO COMPANY, LIMITED (JP) | 2010-02-11 | — | — | US | disclosed |
| US-20100035976-A1 | Method of treating a tumor or a viral disease by administering a 2' , 5' -oligoadenylate analog | SANKYO COMPANY, LIMITED (JP) | 2010-02-11 | — | — | US | disclosed |
| US-7651999-B2 | phosphorothioate modification containg oligonadenylates useful as antiviral, anticarcinogenic and antitumor agent; stable and have superior activity for treating lung cancer | SANKYO COMPANY, LIMITED (JP) | 2010-01-26 | — | — | US | disclosed |
| US-7651999-B2 | phosphorothioate modification containg oligonadenylates useful as antiviral, anticarcinogenic and antitumor agent; stable and have superior activity for treating lung cancer | SANKYO COMPANY, LIMITED (JP) | 2010-01-26 | — | — | US | disclosed |
| EP-1806350-A2 | Amphipatic polycarboxylic chelates and complexes with paramagnetic metals as MRI contrast agents | BRACCO International B.V. (NL) | 2007-07-11 | — | — | EP | disclosed |
| EP-1153029-B1 | AMPHIPATIC POLYCARBOXYLIC CHELATES AND COMPLEXES WITH PARAMAGNETIC METALS AS MRI CONTRAST AGENTS | BRACCO INT BV (NL) | 2007-01-10 | — | — | EP | disclosed |
| US-6652834-B2 | Tensioactive properties, long lasting activity in the blood pool | BRACCO INTERNATIONAL B.V. (NL) | 2003-11-25 | — | — | US | disclosed |
| US-20020168321-A1 | ADMINISTRABLE MRI COMPOSITIONS FOR ENHANCING THE CONTRAST BETWEEN REGIONS IN ORGANS | BRACCO RESEARCH S.A. (CH) | 2002-11-14 | — | — | US | disclosed |
| US-20020098152-A1 | Amphipatic polycarboxylic chelates and complexes with paramagnetic metals as MRI contrast agents | BRACCO INTERNATIONAL B.V. | 2002-07-25 | — | — | US | disclosed |
| US-6342598-B1 | BLOOD-POOL CONTRAST AGENTS OF OUTSTANDING LONG LIFE IN CIRCULATION | BRACCO INTERNATIONAL B.V. (NL) | 2002-01-29 | — | — | US | disclosed |
| EP-1153029-A2 | AMPHIPATIC POLYCARBOXYLIC CHELATES AND COMPLEXES WITH PARAMAGNETIC METALS AS MRI CONTRAST AGENTS | BRACCO INTERNATIONAL B.V. (NL) | 2001-11-14 | — | — | EP | disclosed |
| EP-1105162-A1 | COMBINATION OF A POSITIVE MRI CONTRAST AGENT WITH A NEGATIVE MRI CONTRAST AGENT | BRACCO RESEARCH S.A. (CH) | 2001-06-13 | — | — | EP | disclosed |
| WO-2000030688-A2 | AMPHIPATIC POLYCARBOXYLIC CHELATES AND COMPLEXES WITH PARAMAGNETIC METALS AS MRI CONTRAST AGENTS | BRACCO INTERNATIONAL B.V. (NL) | 2000-06-02 | — | — | WO | disclosed |
| WO-2000009170-A1 | COMBINATION OF A POSITIVE MRI CONTRAST AGENT WITH A NEGATIVE MRI CONTRAST AGENT | BRACCO RESEARCH S.A. (CH) | 2000-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020098152-A1 | Amphipatic polycarboxylic chelates and complexes with paramagnetic metals as MRI contrast agents | SLC39A14, HAMP, PICALM | CASP2 4719/4885NAAA 692/4885EPHX1 4854/4885 |
| US-20100035976-A1 | Method of treating a tumor or a viral disease by administering a 2' , 5' -oligoadenylate analog | ADAR, NSUN2, ADORA3 | CASP2 2647/4885NAAA 1913/4885EPHX1 1687/4885 |
| US-20020168321-A1 | ADMINISTRABLE MRI COMPOSITIONS FOR ENHANCING THE CONTRAST BETWEEN REGIONS IN ORGANS | CD68, FABP1, TNNC1 | CASP2 4045/4885NAAA 867/4885EPHX1 1720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.